Malaria drug could be key to fighting blood cancer
NCT ID NCT07022743
Summary
This study is testing if adding an affordable malaria drug, artesunate, to the standard leukemia drug imatinib works better than imatinib alone. It aims to help patients, particularly in Nigeria, where access to stronger second-line treatments is limited. The trial will see if the combination is safe and helps more patients achieve a deep remission, even if their initial response to imatinib was suboptimal.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA (CML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Obafemi Awolowo University Teaching Hospital Complex, Ile-Ife
Ile-Ife, Osun State, 3408, Nigeria
Conditions
Explore the condition pages connected to this study.